Back to Stakeholders
EmpathBio Inc. is an ATAI Life Sciences subsidiary developing EMP-01, an MDMA derivative designed to preserve entactogenic therapeutic properties while reducing cardiovascular and stimulant side effects, with PTSD as the primary indication. The company completed a Phase 1 trial of EMP-01 in 32 healthy volunteers in New Zealand.
Quick Facts
- Type
- Subsidiary
- HQ
- United States
- Website
- Visit